Browse CP

Summary
SymbolCP
Nameceruloplasmin (ferroxidase)
Aliases CP-2; Ferroxidase; Ceruloplasmin
Chromosomal Location3q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted. Note=Colocalizes with GCP1 in secretory intracellular compartments.
Domain PF00394 Multicopper oxidase
PF07731 Multicopper oxidase
PF07732 Multicopper oxidase
Function

Ceruloplasmin is a blue, copper-binding (6-7 atoms per molecule) glycoprotein. It has ferroxidase activity oxidizing Fe(2+) to Fe(3+) without releasing radical oxygen species. It is involved in iron transport across the cell membrane. Provides Cu(2+) ions for the ascorbate-mediated deaminase degradation of the heparan sulfate chains of GPC1. May also play a role in fetal lung development or pulmonary antioxidant defense (By similarity).

> Gene Ontology
 
Biological Process GO:0000041 transition metal ion transport
GO:0006825 copper ion transport
GO:0006875 cellular metal ion homeostasis
GO:0006879 cellular iron ion homeostasis
GO:0046916 cellular transition metal ion homeostasis
GO:0055072 iron ion homeostasis
GO:0055076 transition metal ion homeostasis
Molecular Function GO:0004322 ferroxidase activity
GO:0005507 copper ion binding
GO:0016722 oxidoreductase activity, oxidizing metal ions
GO:0016724 oxidoreductase activity, oxidizing metal ions, oxygen as acceptor
GO:0051087 chaperone binding
Cellular Component GO:0005765 lysosomal membrane
GO:0072562 blood microparticle
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG hsa00860 Porphyrin and chlorophyll metabolism
Reactome R-HSA-917937: Iron uptake and transport
R-HSA-425410: Metal ion SLC transporters
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-425366: Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
Summary
SymbolCP
Nameceruloplasmin (ferroxidase)
Aliases CP-2; Ferroxidase; Ceruloplasmin
Chromosomal Location3q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCP
Nameceruloplasmin (ferroxidase)
Aliases CP-2; Ferroxidase; Ceruloplasmin
Chromosomal Location3q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCP
Nameceruloplasmin (ferroxidase)
Aliases CP-2; Ferroxidase; Ceruloplasmin
Chromosomal Location3q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0950.895
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0160.441
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.9050.408
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4170.342
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.590.724
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2050.917
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7010.439
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.2530.361
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0660.965
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.1690.577
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.2810.676
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-1.0960.00425
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolCP
Nameceruloplasmin (ferroxidase)
Aliases CP-2; Ferroxidase; Ceruloplasmin
Chromosomal Location3q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCP
Nameceruloplasmin (ferroxidase)
Aliases CP-2; Ferroxidase; Ceruloplasmin
Chromosomal Location3q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCP
Nameceruloplasmin (ferroxidase)
Aliases CP-2; Ferroxidase; Ceruloplasmin
Chromosomal Location3q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCP
Nameceruloplasmin (ferroxidase)
Aliases CP-2; Ferroxidase; Ceruloplasmin
Chromosomal Location3q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCP
Nameceruloplasmin (ferroxidase)
Aliases CP-2; Ferroxidase; Ceruloplasmin
Chromosomal Location3q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCP
Nameceruloplasmin (ferroxidase)
Aliases CP-2; Ferroxidase; Ceruloplasmin
Chromosomal Location3q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CP collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CP.
ID Name Drug Type Targets #Targets
DB00055Drotrecogin alfaBiotechCP, F2, F5, F8, GGCX, PF4, PROCR, PROS1, SERPINA5, SERPINB6, SERPI ......12
DB01373CalciumSmall MoleculeALPP, AOC1, ATP2C1, BMP4, CACNA1C, CAST, COMP, CP, MGP, PCDH19, PD ......19
DB01592IronSmall MoleculeAHSP, CP, EGLN1, FEN1, FTH1, FXN, HBA1, HDAC8, NEIL1, NEIL2, POLB, ......13
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119